Literature DB >> 16271546

Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus.

Jeffrey C Laurence1.   

Abstract

All persons at risk for infection with human immunodeficiency virus (HIV) types 1 and 2, including men who have sex with men, those with multiple heterosexual contacts, abusers of illegal injection drugs, and persons frequently exposed to blood and blood products, are also at high risk for hepatitis A virus (HAV) and acute and chronic hepatitis B virus (HBV) infections. HIV can prolong the duration and increase the level of HAV viremia and augment HAV-related liver abnormalities. HIV also magnifies HBV viremia and the risk of HBV reactivation, chronic active HBV infection, cirrhosis, and death. Because of these concerns, hepatitis A vaccination is recommended for all HIV-positive/HAV seronegative persons, with 2 standard doses given 6 to 12 months apart. Immune response to hepatitis A vaccines is excellent, even in moderately immune-suppressed individuals. Hepatitis B vaccination is also recommended for all HIV-positive persons lacking prior immunity. However, immune reactivity to hepatitis B vaccines is frequently suboptimal in terms of patients' rate of response, antibody titer, and durability. Relatively high CD4+ T-cell counts (> or =500/mm3) and low levels of HIV viremia (<1,000 RNA genome copies/mL plasma) are necessary to ensure adequate hepatitis B vaccine response. Higher hepatitis B vaccine doses, prolongation of the vaccination schedule, or both, as prescribed for many patients with non-HIV-related immune deficiencies, may be considered initially. Revaccination should be instituted if postvaccination titers of antibodies to hepatitis B surface antigen are <10 mIU/mL (<10 IU/L). Nonresponders may also react to a subsequent vaccine course if CD4+ T-cell counts rise to 500/mm3 following institution of highly active antiretroviral therapy; vaccine adjuvant trials are under way. Universal, age-based immunization of all young and middle-aged adults appears to be the most comprehensive way of protecting all populations who are at high risk.

Entities:  

Mesh:

Year:  2005        PMID: 16271546     DOI: 10.1016/j.amjmed.2005.07.024

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

1.  Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.

Authors:  Celine A Hayden; Stephen J Streatfield; Barry J Lamphear; Gina M Fake; Todd K Keener; John H Walker; John D Clements; Debra D Turner; Ian R Tizard; John A Howard
Journal:  Vaccine       Date:  2012-03-08       Impact factor: 3.641

Review 2.  Viral hepatitis in HIV infection.

Authors:  Margaret James Koziel; Marion G Peters
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

Review 3.  Hepatitis B virus vaccination in HIV-infected people: A review.

Authors:  François-Xavier Catherine; Lionel Piroth
Journal:  Hum Vaccin Immunother       Date:  2017-02-16       Impact factor: 3.452

4.  Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.

Authors:  Stephanie B Troy; Diana Kouiavskaia; Julia Siik; Efrat Kochba; Hind Beydoun; Olga Mirochnitchenko; Yotam Levin; Nancy Khardori; Konstantin Chumakov; Yvonne Maldonado
Journal:  J Infect Dis       Date:  2015-01-07       Impact factor: 5.226

5.  Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection.

Authors:  S B Troy; A E B Rossheim; J Siik; T D Cunningham; J A Kerry
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

6.  Efficacy of Hepatitis B Vaccination among Children in Special Region of Yogyakarta, Indonesia: Evaluation of Humoral and Cellular Immunity.

Authors:  Caessar Pronocitro; Nenny Sri Mulyani; Afif Avicenna Ghufron; Yugata Halimawan Hazazi; Bambang Ardianto; Didik Setyo Heriyanto
Journal:  Kobe J Med Sci       Date:  2018-01-17

7.  Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Kenneth Wilkins; Andrew W Lee; Anthony Grosso; Michael L Landrum; Amy Weintrob; Anuradha Ganesan; Jason Maguire; Stephanie Klopfer; Carolyn Brandt; William P Bradley; Mark R Wallace; Brian K Agan
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

8.  Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy.

Authors:  Mark J Abzug; Meredith Warshaw; Howard M Rosenblatt; Myron J Levin; Sharon A Nachman; Stephen I Pelton; William Borkowsky; Terence Fenton
Journal:  J Infect Dis       Date:  2009-09-15       Impact factor: 5.226

9.  Supercritical fluid extraction provides an enhancement to the immune response for orally-delivered hepatitis B surface antigen.

Authors:  Celine A Hayden; Emily M Smith; Debra D Turner; Todd K Keener; Jeffrey C Wong; John H Walker; Ian R Tizard; Rafael Jimenez-Flores; John A Howard
Journal:  Vaccine       Date:  2014-01-28       Impact factor: 3.641

10.  Hepatitis a and e infection in international travellers.

Authors:  Joseph Torresi; Douglas Johnson
Journal:  Curr Infect Dis Rep       Date:  2011-06       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.